HomepageEarnings Events Newsdesk 22 hours ago Johnson & Johnson (JNJ) FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA) Johnson & Johnson (NYSE: JNJ) FY 2026 Other Release AbbVie (ABBV) AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease » « Microchip Technology Inc (MCHP) Microchip Increases Manufacturing Capacity of its Hydrogen Masers Newsdesk:
